Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02794493
Recruitment Status : Completed
First Posted : June 9, 2016
Last Update Posted : July 25, 2019
Sponsor:
Information provided by (Responsible Party):
Yanni Lou, China-Japan Friendship Hospital

Brief Summary:

RATIONALE: Hand foot syndrome may be treated or reduced by soaking Traditional Chinese Medicine Formula LC09 in patients receiving capecitabine for colorectal and/or breast cancer.

PURPOSE: This randomized phase III trial is studying soaking Traditional Chinese Medicine Formula LC09 to see how well they work compared to placebos in preventing hand-foot syndrome in patients who are receiving capecitabine for colorectal or breast cancer.


Condition or disease Intervention/treatment Phase
Hand Foot Syndrome Drug: Traditional Chinese Medicine Formula LC09 Other: Placebo Phase 3

Detailed Description:

OBJECTIVES:

OBJECTIVES: Determine whether Traditional Chinese Medicine Formula LC09 can treat or reduce the severity of capecitabine-caused hand foot syndrome.

Evaluate the potential toxicity of Traditional Chinese Medicine Formula LC09. OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled study. Patients are randomized to 2 treatment arms.

Arm I: Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.

Arm II: Patients receive placebo by soaking their affected hand and feet 20 min twice daily.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 156 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of Traditional Chinese Medicine Formula LC09 for Treatment of Capecitabine-Induced Hand and Foot Syndrome
Actual Study Start Date : April 1, 2015
Actual Primary Completion Date : December 31, 2017
Actual Study Completion Date : April 25, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Foot Health

Arm Intervention/treatment
Experimental: Arm I
Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
Drug: Traditional Chinese Medicine Formula LC09
Placebo Comparator: Arm II
Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
Other: Placebo



Primary Outcome Measures :
  1. Grade of hand foot syndrome over time as measured by NCI CTCAE version 4.03 PPE syndrome criteria [ Time Frame: Once daily until the date that the consecutive 2 cycles of capecitabine-containing chemotherapy ended (up to 6 weeks) ]
    Grading of PPE by NCI CTC criteria is collected on a diary card that subjects fill out once daily. Investigators assess and fill the grading into the case report form every week.

  2. Assessment of patient reported pain using a 1-10 score. [ Time Frame: Once daily until the date that the consecutive 2 cycles of capecitabine-containing chemotherapy ended(up to 6 weeks) ]
    Assessment of patient reported pain using a 1-10 score is collected on a diary card that subjects fill out once daily.


Secondary Outcome Measures :
  1. Instrumental Activities of Daily Living Scale [ Time Frame: Baseline and after the intervention completed (up to 6 weeks) ]
    Performance assessment on 8 daily tasks

  2. Dermatology Life Quality Index (DLQI) Total Score [ Time Frame: Baseline and after the intervention completed (up to 6 weeks) ]
    The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

  3. Chemotherapy completion rate [ Time Frame: After the intervention completed (up to 6 weeks) ]
    Proportion of patients having tolerated established 2-week chemotherapy in each arms.

  4. Incidence of reduced dosage of capecitabine thereby [ Time Frame: After the intervention completed (up to 6 weeks) ]
    Reduced dosage of capecitabine thereby because of hand foot syndrome

  5. Incidence of cessation of capecitabine thereby [ Time Frame: After the intervention completed (up to 6 weeks) ]
    Cessation of capecitabine thereby because of hand foot syndrome



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must meet the following criteria to be eligible for the study:

  1. Histologically confirmed colorectal cancer or breast cancer, of which colorecta cancer is advanced or undergoing adjuvant therapy after radical resection and breast cancer is at the stage of recurrence or metastasis;
  2. Level 1 or above HFS after receiving capecitabine as part of routine standard care;
  3. Plan to receive capecitabine as part of routine more than 2 weeks;
  4. ECOG performance status 0-2;
  5. Life expectancy greater than or equal to 3 months;
  6. No serious heart, liver, kidney and other important viscera dysfunction, as defined below:

    • absolute neutrophil count greater than or equal to 1.5 x 10(9)/L
    • platelet count greater than or equal to 100 x 10(9)/L
    • hemoglobin greater than or equal to 9.0 g/dL
    • total bilirubin less than or equal to 1.5 times the ULN
    • AST/SGOT and ALT/SGPT less than or equal to 2.5 times the ULN (or less than or equal to 5 times the ULN if liver function abnormalities due to underlying malignancy)
    • creatinine less than or equal to 1.5 times the ULN
    • creatinine clearance greater than or equal to 60 ml/min (by Cockcroft-Gault)
  7. Ability to cooperate with HFS grade evaluation, understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Subjects meeting any of the following criteria are ineligible for study entry:

  1. Concurrent with level 1 or above peripheral neuropathy (such as diabetic neuropathy or chemotherapy induced peripheral neuropathy);
  2. Other acute or chronic inflammatory conditions or infections of the hands or feet that would complicate safety, application of topical creams, or study endpoints;
  3. Currently taking other treatment for PPE (including topical urea cream, pyridoxine, celecoxib, compound matrine injection and deproteinized calf blood extractive injection);
  4. History of severe or uncontrolled organic disease or infection, such as heart, pulmonary or renal failure that cause the termination of chemotherapy;
  5. Pregnant (positive pregnancy test) or nursing women;
  6. Participating in other clinical trial currently or within 4 weeks.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yanni Lou, Attending Doctor, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier: NCT02794493    
Other Study ID Numbers: 2015BAI04B07
First Posted: June 9, 2016    Key Record Dates
Last Update Posted: July 25, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Hand-Foot Syndrome
Syndrome
Disease
Pathologic Processes
Drug Eruptions
Dermatitis
Skin Diseases
Drug Hypersensitivity
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders